Nephrology News
Cabozantinib Improves Survival, Response in Bone-metastatic RCC
Patients who received cabozantinib were also less likely to have skeletal-related events (23% vs 29% with everolimus).
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/